Screener
Vor Biopharma VOR Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Restricted cash | 168 | 168 |
| Property and equipment, net | 565 | 533 |
| Operating lease right-of-use assets | 2,827 | 2,936 |
| Other assets | 2,408 | 2,384 |
| Total assets | $506,746 | $464,126 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,043 | $5,127 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's deferred tax assets and other non-current assets?
- Vor Biopharma (VOR) reported deferred tax assets and other non-current assets of $2.41M in Q1 2026.
- How has Vor Biopharma's deferred tax assets and other non-current assets changed year-over-year?
- Vor Biopharma's deferred tax assets and other non-current assets increased by 1.6% year-over-year, from $2.37M to $2.41M.
- What is the long-term trend for Vor Biopharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Vor Biopharma's deferred tax assets and other non-current assets has grown at a -6.8% compound annual growth rate (CAGR), from $3.4M to $2.38M.
Ask your AI about Vor Biopharma's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude